



## Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

February 4, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 4, 2025-- [Veracyte, Inc.](#) (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company's website and will be available via the following link: <https://edge.media-server.com/mmc/p/8em9yd38>. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at <https://investor.veracyte.com/events-presentations>.

The conference call dial-ins can be accessed by registering at: <https://register.vevent.com/register/Bld0a04e7e33824346ad0b7e5eb4eb2525>

### About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit [www.veracyte.com](http://www.veracyte.com) or follow us on [LinkedIn](#) or [X \(Twitter\)](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250204129697/en/): <https://www.businesswire.com/news/home/20250204129697/en/>

### Investors:

Shayla Gorman  
[investors@veracyte.com](mailto:investors@veracyte.com)  
(619) 393-1545

### Media:

Tracy Morris  
[media@veracyte.com](mailto:media@veracyte.com)  
(650) 380-4413

Source: Veracyte, Inc.